Osteoporosis | Xconomy

by in

Entry	Blogger	Date	Location
Five Red Flags of a Biotech, Pathway Medical Learns Lessons, Amgen Faces FDA Delay, & More Seattle-Area Life Sciences News	Luke Timmerman	10/22/09	Seattle
Amgen’s Dmab Faces FDA Delay	Luke Timmerman	10/19/09	Seattle
Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent	Luke Timmerman	10/09/09	National
Amgen’s Dmab Works in Cancer Trial	Luke Timmerman	07/07/09	Seattle
Soteira Snags $6.6M in Equity Round	Ryan McBride	05/08/09	Boston
Amgen Cuts 100 Jobs in Bothell	Luke Timmerman	04/09/09	Seattle
Swype Scores $1.3M, Onehub Raises $600K, Genzyme Comes to Town, & More Seattle-Area Deals News	Gregory T. Huang	04/07/09	Seattle
MDRNA Sells Osteoporosis Drug	Luke Timmerman	04/01/09	Seattle
Amgen Seeks FDA Nod For Bone Drug	Luke Timmerman	12/19/08	Seattle
MDRNA Gets Tentative FDA Approval	Luke Timmerman	12/15/08	Seattle
Amgen Scientist, After 13-Year Push, Sees Bone Cancer Work Paying Dividends	Luke Timmerman	10/29/08	Seattle
Amgen’s Dmab Cuts Fracture Risk for Osteoporosis Patients, Just What Investors Wanted to See	Luke Timmerman	09/16/08	Seattle
Amgen Osteoporosis Drug Reduces Bone Fractures in Pivotal Study	Luke Timmerman	07/25/08	Seattle
Page 1 of 1

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.